122 related articles for article (PubMed ID: 20117851)
1. Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk.
Rovati GE; Sala A; Capra V; Dahlén SE; Folco G
Trends Pharmacol Sci; 2010 Mar; 31(3):102-7. PubMed ID: 20117851
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Fosslien E
Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of thromboxane receptors by diclofenac and lumiracoxib.
Selg E; Buccellati C; Andersson M; Rovati GE; Ezinga M; Sala A; Larsson AK; Ambrosio M; Låstbom L; Capra V; Dahlén B; Ryrfeldt A; Folco GC; Dahlén SE
Br J Pharmacol; 2007 Dec; 152(8):1185-95. PubMed ID: 17965743
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition.
Hoxha M; Buccellati C; Capra V; Garella D; Cena C; Rolando B; Fruttero R; Carnevali S; Sala A; Rovati GE; Bertinaria M
Pharmacol Res; 2016 Jan; 103():132-43. PubMed ID: 26621246
[TBL] [Abstract][Full Text] [Related]
5. Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk.
Carnevali S; Buccellati C; Bolego C; Bertinaria M; Rovati GE; Sala A
Curr Med Chem; 2017; 24(30):3218-3230. PubMed ID: 28571535
[TBL] [Abstract][Full Text] [Related]
6. Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors.
Bertinaria M; Shaikh MA; Buccellati C; Cena C; Rolando B; Lazzarato L; Fruttero R; Gasco A; Hoxha M; Capra V; Sala A; Rovati GE
ChemMedChem; 2012 Sep; 7(9):1647-60. PubMed ID: 22865828
[TBL] [Abstract][Full Text] [Related]
7. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC
Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
9. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA; Derry S; McQuay HJ
BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
[TBL] [Abstract][Full Text] [Related]
10. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
11. The pharmacology of selective inhibition of COX-2.
Grosser T
Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913
[TBL] [Abstract][Full Text] [Related]
12. COX-2 inhibitors and cardiovascular risk.
Funk CD; FitzGerald GA
J Cardiovasc Pharmacol; 2007 Nov; 50(5):470-9. PubMed ID: 18030055
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal antiinflammatory drugs: past, present and future.
Patrono C; Rocca B
Pharmacol Res; 2009 May; 59(5):285-9. PubMed ID: 19416627
[TBL] [Abstract][Full Text] [Related]
14. The murky waters of the coxibs: a review of the current state of play.
Ostor AJ; Hazleman BL
Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
[TBL] [Abstract][Full Text] [Related]
15. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
Hermann M; Ruschitzka F
Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
[TBL] [Abstract][Full Text] [Related]
16. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population.
Capone ML; Tacconelli S; Rodriguez LG; Patrignani P
Pharmacol Rep; 2010; 62(3):530-5. PubMed ID: 20631418
[TBL] [Abstract][Full Text] [Related]
17. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
[TBL] [Abstract][Full Text] [Related]
18. COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Marwali MR; Mehta JL
Thromb Haemost; 2006 Oct; 96(4):401-6. PubMed ID: 17003914
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Martínez-González J; Badimon L
Curr Pharm Des; 2007; 13(22):2215-27. PubMed ID: 17691994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
